A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Dec 2017 According to an Eli Lilly media release, the US FDA has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. The BLA submission was based on the results from EVOLVE-1, EVOLVE-2 and REGAIN studies.
    • 06 Nov 2017 The trial has been completed in Czech Republic.
    • 11 Sep 2017 Results from EVOLVE-1 and EVOLVE-2 studies, presented at the 18th Congress of the International Headache Society 2017, according to The International Headache Society media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top